Document:

<PAGE>

                                                                   EXHIBIT 10.59

                             TERMINATION AGREEMENT

This Termination Agreement (the "Termination Agreement") is made as of the 24th
day of October, 2001 (the "Effective Date") by and between Andrx Labs, Inc.,
formerly known as Aura Laboratories, Inc. ("Andrx Labs"), Andrx Pharmaceuticals,
Inc. ("Pharmaceuticals") and Anda, Inc., formerly known as Anda Generics, Inc.
("Anda"), each of which is a subsidiary of Andrx Corporation ("Andrx"), and
Geneva Pharmaceuticals, Inc. ("Geneva" and collectively with the other
signatories hereto, the "Parties").

WHEREAS:

A Product Distribution, Development and Licensing Agreement was executed as of
the 1/st/ day of May, 1999 by the Parties and Global Generics Sector of Novartis
AG ("Novartis Generics"), which agreement was amended by Amendment Number 1,
Amendment Number 2, Amendment Number 3 and Amendment Number 4 (collectively, the
"Agreement"); and

The Parties have determined that it is in their mutual best interest to
terminate the Agreement and for Geneva to transfer all of its right, title and
interest in and to the Andrx Products to Andrx on the terms and conditions
herein set forth;

NOW, THEREFORE, the parties agree as follows:

1.   Capitalized Terms. All capitalized terms not defined herein shall have the
     -----------------
     meaning ascribed to them in the Agreement.

2.   Termination of Agreement. The Agreement and all covenants and provisions
     ------------------------
     thereof are terminated as of the Effective Date and the parties shall be
     released from all obligations to one another in accordance with the
     following terms and conditions:

     A.   All requirements of Anda to purchase Geneva Products pursuant to the
          Agreement are terminated as of the Effective Date. In conjunction with
          entering into the Agreement, Anda and Geneva entered into a Supply
          Agreement dated December 18, 1998 (that supply agreement including all
          subsequent agreed to modifications is now defined as the "Supply
          Agreement"). Notwithstanding the termination of Anda's obligation to
          purchase certain minimum amounts of Geneva Products, the Parties agree
          that Anda is an authorized distributor for Geneva under the terms of
          the Supply Agreement. Until such time as the parties enter into a new
          Customer Purchase Agreement, the existing Supply Agreement shall
          continue to apply.

     B.   In consideration of Geneva's performance, to date, under the Agreement
          and its agreement herein to relinquish all of its rights in and to the
          Andrx Products, Andrx herein agrees to make the payments set forth on
          Exhibit A-1 to Geneva, within ten days of the event therein described.

          In addition to the payments, Andrx shall pay Geneva a royalty on the
          Net Sales from the sale of Metformin in the United States on a
          quarterly basis for a term of five (5) years in accordance with the
          schedule attached hereto as Exhibit A-2. For purposes of this
          Termination Agreement, Net Sales shall mean the actual gross amount
          invoiced by Andrx and its Affiliates to their non-Affiliated customers
          for the sale of Metformin Extended Release, less customary discounts,
          returns, promotional allowances, volume and incentive rebates, shelf
          stock adjustments and other similar customary adjustments or
          allowances actually accrued in accordance with U.S. GAAP to such
          customers in the normal course of business by Andrx or its Affiliates.
<PAGE>

     C.   Maintenance of Records; Inspection. Andrx shall maintain complete and
          ----------------------------------
          accurate books and records in connection with the sale of Metformin
          Extended Release by Andrx and its Affiliates to their non-Affiliated
          customers in the normal course of business by Andrx or its Affiliates
          ("Commercial Sales"). Such books and records shall be made available
          from time to time and upon reasonable prior written notice to Andrx
          for review and audit by outside auditors who are not affiliated with
          either Party or their respective Affiliates and who are reasonably
          acceptable to the Party whose books and records are to be audited
          ("Auditors"). The cost of such audit shall be borne by the Party
          requesting such audit unless such audit shows that the audited Party
          overstated the amount which it was entitled to receive or understated
          the amount which the auditing Party was entitled to receive by two and
          one-half (2.5%) percent or more ("Excessive Error") in which event the
          Party whose records were audited shall reimburse the other Party for
          the cost of such audit. Any such audit shall be scheduled during
          regular business hours within two (2) weeks after the Party whose
          books and records are to be audited and the Party requesting such
          audit have agreed upon the Auditors to be employed. Such Auditors
          shall not disclose any information to the Party requesting such audit
          other than whether in their opinion the Commercial Sales have been
          properly calculated or reported, or if in their opinion they have not
          been accurately reported, then the extent of any inaccuracy. The
          Auditors and the auditors of the Party whose books and records were
          examined shall meet to resolve any differences of opinion, and, if
          such differences cannot be resolved within thirty (30) days, then they
          shall choose a third accounting firm to resolve such differences. If
          they are unable to agree upon a third accounting firm within sixty
          (60) days after the Auditors have presented their initial findings,
          then either Party may apply to the American Arbitration Association to
          have a third accounting firm appointed to resolve such differences
          ("Independent Accounting Firm"). The decision of the Independent
          Accounting Firm shall be final and binding upon the Parties. The fees
          and expenses of the Independent Accounting Firm shall be borne equally
          by the Parties except if the decision of such Independent Accounting
          Firm confirms that an Excessive Error was made in which event the fees
          of the Independent Accounting Firm shall be borne solely by the Party
          who committed the Excessive Error. The Auditors shall, before
          commencing their audit, execute a confidentiality agreement in form
          and substance reasonably satisfactory to the Party whose books and
          records are being audited.

3.   Publicity. Neither Geneva nor Andrx shall publicly disclose the continuing
     ---------
     financial terms reflected in the attachments to this Termination Agreement
     or the products covered by the Agreement, without the other's written
     consent, unless required by law.

4.   Notices. Any notice or other communication required or desired to be given
     -------
     to any Party under this Termination Agreement shall be in writing and shall
     be deemed given when: (i) deposited in the United States mail, first-class
     postage prepaid, and addressed to that Party at the address for such Party
     set forth at the end of this Termination Agreement; (ii) delivered to
     Federal Express, Airborne, or any other similar express delivery service
     for delivery to that Party at that address; or (iii) sent by facsimile
     transmission, with electronic confirmation, to that Party at its facsimile
     number set forth at the end of this Termination Agreement. Any Party may
     change its address or facsimile number for notices under this Termination
     Agreement by giving the other Party notice of such change.

5.   Governing Law; Venue. All questions concerning the validity or meaning of
     --------------------
     this Termination Agreement or relating to the rights and obligations of the
     Parties with respect to performance under this Termination Agreement shall
     be construed and resolved under the laws of the State of Delaware. The
     Parties hereby designate: the courts of the State of New York as the court
     of proper jurisdiction and venue for any actions or proceedings relating to
     this Termination Agreement if such action or proceeding if commenced by
     Geneva/Novartis Generics and the courts of the State of Florida if such
     action or proceeding is commenced by Andrx; irrevocably consent to such
     designation, jurisdiction, and venue; and waive any obligations or defenses
     relating to jurisdiction or venue with respect to any actions or
     proceedings initiated in such court.

6.   No Implied Waivers; Rights Cumulative. No failure on the part of Geneva or
     -------------------------------------
     Andrx to exercise and no delay in exercising any right, power, remedy or
     privilege under this Termination Agreement or provided by statute or at law
     or in equity or otherwise, including, without limitation, the right or
     power to terminate this Termination Agreement, shall impair, prejudice or
     constitute a waiver of any such right, power, remedy or privilege or be
     construed as a waiver of any breach of this Termination Agreement or as an
     acquiescence therein, nor shall any single or partial exercise of any such
     right, power, remedy or privilege preclude any other or further exercise
     thereof or the exercise of any other right, power, remedy or privilege.
<PAGE>

7.   Complete Agreement. This Termination Agreement and the attachments referred
     ------------------
     to herein contain the entire agreement between the Parties and supersedes
     all prior or contemporaneous discussions, negotiations, representations,
     warranties, or agreements. No changes to this Termination Agreement will be
     made or be binding on either Party unless made in writing and signed by
     each Party.

8.   Signature Authority. Each signatory to this Termination Agreement
     -------------------
     represents and warrants to the other that he or she has signature authority
     and is empowered on behalf of his or her respective Party to execute this
     Termination Agreement.

9.   Attorneys' Fees. Except as otherwise set forth in this Termination
     ---------------
     Agreement, all costs and expenses, including reasonable attorneys' fees,
     incurred in the enforcement of this Termination Agreement, shall be paid to
     the prevailing Party by the non-prevailing Party, upon demand.

10.  Counterparts This Termination Agreement may be executed in one or more
     ------------
     counterparts, all of which may be considered one and the same agreement and
     each of such counterparts shall be deemed an original.

11.  No Partnership or Other Relationship. Nothing contained in this Termination
     ------------------------------------
     Agreement is intended nor shall be deemed or construed to (i) create a
     partnership or joint venture between the Parties, (ii) cause any Party to
     be responsible for the debts, liabilities, obligations, and expenses of the
     other or any of the Party's officers, directors, employees, independent
     contractors or agents, or (iii) substitute any Party for the other Party's
     officers, directors, employees, independent contractors or agents.

                          [INTENTIONALLY LEFT BLANK]
<PAGE>

IN WITNESS WHEREOF, the Parties hereto, through their duly authorized officers,
have set their hands and do hereby agree to the terms set forth above on the
date first written above.

ANDRX LABS, INC.                         ANDA, INC.

By:    /s/ Angelo C. Malahias            By:    /s/ Angelo C. Malahias
       ------------------------------           ------------------------------
Title: VP. and CFO                       Title: VP. and CFO
       ------------------------------           ------------------------------
Date:  October 24, 2001                  Date:  October 24, 2001
       ------------------------------           ------------------------------
Address:                                 Address:
2915 Weston Road                         2915 Weston Road
-------------------------------------    -------------------------------------
Weston, FL 33331                         Weston, FL 33331
-------------------------------------    -------------------------------------
Telephone Number: ___________________    Telephone Number: ___________________
Facsimile Number:  __________________    Facsimile Number:  __________________

ANDRX PHARMACEUTICALS, INC.              GENEVA PHARMACEUTICALS, INC.

By:    /s/ Angelo C. Malahias            By:    /s/ Joseph D. Renner
       ------------------------------           ------------------------------
Title: VP. and CFO                       Title: Chief Operating Officer
       ------------------------------           ------------------------------
Date:  October 24, 2001                  Date:  October 24, 2001
       ------------------------------           ------------------------------
Address:                                 Address:
2915 Weston Road                         101 Morgan Lane
-------------------------------------    -------------------------------------
Weston, FL 33331                         Plainsboro, NJ 08536
-------------------------------------    -------------------------------------
Telephone Number: ___________________    Telephone Number: ___________________
Facsimile Number:  __________________    Facsimile Number:  __________________
<PAGE>

                                  Exhibit A-1

                                    Payments
<TABLE>
<S>                                                                                                      <C>
         ------------------------------------------------------------------------------------------------------
(i)      Upon completion of trial 301 study report, but in no event later than December 31, 2001.        (*)
         ------------------------------------------------------------------------------------------------------
(ii)     Upon filing the NDA for Metformin Extended Release with the FDA.                                (*)
         ------------------------------------------------------------------------------------------------------
(iii)    Upon obtaining the Approvals for Metformin Extended Release.                                    (*)
         ------------------------------------------------------------------------------------------------------
(iv)     Upon the first Commercial Sale of Metformin Extended Release.                                   (*)
         ------------------------------------------------------------------------------------------------------
</TABLE>

(*)  Marked text omitted pursuant to an application for an order for
     confidential treatment by Andrx Corporation.
<PAGE>

                                  Exhibit A-2

                                    Royalty

Andrx shall pay Geneva a (*)% royalty on the Net Sales for the sale of Metformin
Extended Release in the United States on a quarterly basis for a term of five
(5) years in accordance with this schedule.

     ---------------------------------------------------------------
                  Term                                     Royalty
     ---------------------------------------------------------------
     *First year of commercialization                        (*)
     ---------------------------------------------------------------
     Second year of commercialization                        (*)
     ---------------------------------------------------------------
     Third year of commercialization                         (*)
     ---------------------------------------------------------------
     Fourth year of commercialization                        (*)
     ---------------------------------------------------------------
     Fifth year of commercialization                         (*)
     ---------------------------------------------------------------

*    The first year of commercialization shall commence upon the first
     Commercial Sale and shall continue for 364 consecutive days.

**   Provided however that if a third party introduces a fully approved AB rated
     generic version of Metformin Extended Release in years 3 through 5, the
     minimum royalty amount shall be reduced from (*) to (*).

(*)  Marked text omitted pursuant to an application for an order for
     confidential treatment by Andrx Corporation.<PAGE>

                                                                   Exhibit 10.60

                             EMPLOYMENT AGREEMENT

     EMPLOYMENT AGREEMENT, dated this 28th day of September, 2001 ("Effective
Date"), by and between Andrx Corporation ("Company"), a Delaware corporation
with its principal place of business at 4955 Orange Drive, Davie, Florida 33314,
and Scott Lodin ("Executive"), of Aventura, Florida.

     WHEREAS, Company wishes to better assure itself of the continued services
of Executive for the period provided in this Agreement, and Executive is willing
to continue to serve in the employ of Company upon the terms and conditions
hereinafter provided.

     NOW, THEREFORE, in consideration of the mutual covenants herein contained,
the parties hereto hereby agree as follows:

     1.   Employment. Company hereby agrees to employ Executive, and Executive
agrees to enter the employ of Company, upon the terms and conditions herein
provided. For purposes of this Agreement the term "Company" shall mean and
include Andrx Corporation and any of its subsidiaries, whether now in existence
or formed during the term of this Agreement. Executive warrants to Company that
his execution of this Agreement and performance by him of the duties hereunder
will not violate the terms of any other agreements to which Executive is a
party.

     2.   Position and Responsibilities. During the period of his employment
hereunder, Executive agrees to serve as the Company's Executive Vice President,
General Counsel and Secretary, whereby he will be primarily responsible for the
Company's legal affairs, while performing such other duties as may appropriately
be delegated to him from time to time by the Company's Board of Directors, Chief
Executive Officer or President. Executive shall report directly to the Company's
Chief Executive Officer or President. Executive also agrees to serve, if
elected, as an officer and director of any subsidiary of Company without
additional compensation. For purposes of this Agreement, the term "subsidiary"
shall mean any corporation in which Company owns at least a majority of that
corporation's voting stock and at least a majority of each class of that
corporation's nonvoting stock.

     3.   Term of Employment and Duties.

               (A)  Term. Executive's employment shall commence on the Effective
Date and shall continue for a period of sixty (60) calendar months thereafter
("Initial Term"), unless sooner terminated, as provided in Paragraph 6 hereof.
In the event Company and Executive
<PAGE>

agree that Executive should continue in the employ of Company after the end of
the Initial Term, such continued employment shall be subject to the terms and
conditions of this Agreement, except as otherwise provided by the parties in
writing, and shall thereafter expire upon one hundred eighty (180) days written
notice by Company to Executive, upon ninety (90) days notice by Executive to
Company or as otherwise provided in Paragraph 6 (including the Initial Term, the
"Employment Term").

               (B)  Duties. Executive shall devote his full time, attention,
skill and best efforts to the faithful performance of his duties to Company.
Executive shall not engage in any other business or occupation without Company's
written consent; provided, however, nothing contained herein shall prohibit
Executive from making passive or personal investments, provided such investments
do not result in an undisclosed conflict of interest between Executive and
Company. Executive acknowledges that he shall travel as reasonably required
around the United States and abroad in connection with his employment.

     4.   Compensation.

               (A)  Base Compensation. For all services rendered by Executive in
any capacity during his employment under this Agreement, including, without
limitation, services as an executive, officer, director, or member of any
committee of Company, Company, commencing with the Effective Date and for a
period of twelve (12) months thereafter ("base period"), shall pay a base
compensation to Executive at the rate of Three Hundred Twenty Five Thousand
($325,000.00) Dollars per year. For each twelve (12) month period thereafter his
base compensation shall be subject to upward adjustment by the Compensation
Committee of the Board of Directors of Company.

               (B)  Fringe Compensation. In addition to the foregoing, during
each year of employment hereunder, Company shall provide Executive with the
following:

     (1)  Automobile. An automobile allowance of at least $500.00 per month.

     (2)  Medical Insurance and Premium Reimbursement. Medical insurance
coverage for Executive, his spouse and dependent children.

     (3)  Expense Reimbursement. Payment or reimbursement of reasonable travel
and other expenses (including without limitation entertainment expenses incurred
primarily for the benefit of Company) incurred by Executive in performing his
duties under this Agreement and in carrying out and promoting the business of
Company, upon presentation by him, from time to

                                       2
<PAGE>

time, of an itemized account ("vouchers") of such expenditures in such detail as
may reasonably be required by Company.

     (4)  Vacation. Four (4) weeks of vacation with full pay each 12-month
period during the term of this Agreement, at such times as shall be mutually
agreed upon by Executive and the Company's Chief Executive Officer or President.
No portion of any unused vacation time shall be carried over to a subsequent
period, nor shall Executive receive any compensation in addition to that
provided herein for any unused vacation time.

     (5)  Professional Development. During the term of this Agreement, to attend
seminars and conferences relating to the business of Company (with full pay).
Company shall pay or reimburse Executive for all fees, reasonable travel and
other expenses incurred in connection with attendance at such seminars and
conferences. Reimbursements shall be made upon presentation of vouchers by
Executive.

     (6)  Other Benefits. Executive shall also be entitled to receive, and
participate in, any country clubs, pension or profit sharing plan, stock
purchase plan, stock option plan, group life insurance plan, hospitalization
insurance plan, medical services plan, or any other plan of Company now,
heretofore or hereafter existing for the benefit of Executive, and other senior
executives or officers generally.

     5.   Key-Man Insurance. At any time during the term of this Agreement,
Company shall have the right to insure the life of Executive for the sole
benefit of Company, in such amounts, and with such terms, as it may determine.
All premiums payable thereon shall be the obligation of Company. Executive shall
have no interest in any such policy, but shall cooperate with Company in taking
out such insurance by submitting to physical examinations, by supplying all
information required by the insurance company, and by executing all necessary
documents, provided that no financial obligation is imposed upon Executive by
any such documents.

     6.   Termination. This Agreement shall terminate upon the occurrence of any
one of the events set forth below:

     (a)  Cause. Company may, at any time and in its sole discretion, terminate
          -----
the employment of Executive hereunder for Cause, effective as of the date of
written notice (a "Termination Notice") to Executive specifying the nature of
such Cause (the "Termination Date"). For purposes of this Agreement, "Cause"
shall mean (i) Executive's conviction of, or plea of nolo contendere to, a
felony involving a crime of moral turpitude; or (ii) Executive's

                                       3
<PAGE>

having been found guilty, by a court of competent jurisdiction, of commission of
any willfully fraudulent act that is materially adverse to the interest of
Company or of any subsidiary or parent company, provided, however, that the
                                                --------  -------
Termination Notice shall set forth in reasonable detail the act constituting
Cause hereunder, and provided further, that if the act constituting Cause is
                     ----------------
capable of cure, such act is not cured within thirty (30) days following
Executive's receipt of a the Termination Notice . If the employment of Executive
is terminated pursuant to this Section 6(a), Company shall have no further
obligations to Executive hereunder after the Termination Date other than the
payment of salary and benefits accrued and unpaid through the Termination Date.

     (b)  Termination by Company for No Reason. Company may, at any time, and in
          ------------------------------------
its sole discretion, terminate the employment of Executive hereunder for any or
no reason by delivery to him of a Termination Notice. Such termination shall be
effective on the date of the Termination Notice; provided, however, that Company
                                                 --------  -------
shall be obligated to pay Executive severance compensation following the
Termination Date as set forth in Section 7 hereof.

     (c)  Termination by Executive for Good Reason. If at any time during the
          ----------------------------------------
employment term Executive resigns from the employ of Company for Good Reason (as
defined in the next sentence), Company shall be obligated to pay Executive
severance compensation following the Termination Date as set forth in Section 7
hereof. For purposes of this Agreement "Good Reason" shall mean, without the
consent of Executive, if (i) in the good faith determination of Executive,
Executive is no longer designated and/or has the authority of an executive vice
president and chief legal officer of Company or there shall be a change in
Executive's status or responsibilities (including reporting responsibilities)
which does not represent a promotion or Executive shall be assigned duties which
are inconsistent with his status, title, position or duties as executive vice
president and chief legal officer, (ii) there shall occur any material breach by
Company of any material provision of this Agreement which shall remain uncured
for a period of thirty (30) days following receipt by Company of notice from
Executive of his intention to resign because of such breach, or (iii) Executive
is required to regularly work in a location which is 25 or more miles from the
locale at which his work is now engaged.

                                       4
<PAGE>

     (d)   Termination in Case of Disability or Death.
           ------------------------------------------

     (i)   If Executive, due to physical or mental injury, illness, disability
or incapacity, shall fail to render the services provided for in this Agreement
for a consecutive period of six (6) months, Company may, at its option,
terminate Executive's employment hereunder upon fourteen (14) days' written
notice to Executive. Disability shall mean, for purposes of this Agreement,
physical or mental disability preventing Executive from performing his duties
hereunder for the period above specified as determined by the written opinion of
a physician selected in good faith by Company, and agreed to by Executive. If
the employment of Executive is terminated pursuant to this Section 6(d)(i),
Company shall have no further obligations to Executive hereunder after the
Termination Date other than the payment of accrued but unpaid salary and
benefits for a one-year period after the Termination Date.

     (ii)  If Executive shall die during the Employment Term, this Agreement and
Executive's employment hereunder shall terminate immediately upon Executive
death. If the employment of Executive is terminated pursuant to this Section
6(d)(ii), Company shall have no further obligations to Executive hereunder after
the Termination Date other than the payment of accrued but unpaid salary and
benefits for a one-year period after the Termination Date.

     (e)   Executive's Right to Terminate Upon Change of Control. In the event
           -----------------------------------------------------
that at any time during the Employment Term, there is a "Change in Control of
Company" (as hereinafter defined), Executive shall, in the exercise of his sole
discretion and upon the provision of written notice to Company within eighteen
(18) months after the date of such event, be entitled to terminate his
employment hereunder as of the date of provision of such written notice, and
Company shall in such event pay severance compensation following the Termination
Date as set forth in Section 7. As used herein, a "Change in Control of Company"
shall be deemed to have occurred if (i) any person (including any individual,
firm, partnership or other entity) together with all Affiliates and Associates
(as defined under Rule 12b-2 of the General Rules and Regulations promulgated
under the Securities Exchange Act of 1934, as amended (the "Exchange Act") of
such person, but excluding (A) a trustee or other fiduciary holding securities
under an Executive benefit plan of Company or any subsidiary of Company, (B) a
corporation owned, directly or indirectly, by the stockholders of Company in
substantially the proportions as their ownership of Company, (C) Company or any
subsidiary of Company, or (D) Executive, together with all Affiliates and
Associates of Executive, is or becomes the Beneficial Owner (as

                                       5
<PAGE>

defined in Rule 13d-3 promulgated under the Exchange Act), directly or
indirectly, of securities of Company representing 40% of more of the combined
voting power of Company's then outstanding securities, such person being
hereinafter referred to as an Acquiring Person; (ii) individuals who, on the
date hereof, are Continuing Directors shall cease for any reason to constitute a
majority of the Company's Board of Directors ("Board"); or (iii) the
stockholders of Company approve a merger of consolidation of Company with any
other corporation, other than a merger of consolidation that would result in the
voting securities of Company outstanding immediately prior thereto continuing to
represent (either by remaining outstanding or by being converted into voting
securities of the surviving entity) at least 80% of the combined voting power of
the voting securities of Company or such surviving entity outstanding
immediately after such merger or consolidation, or the stockholders or Company
approve a plan of complete liquidation of Company or an agreement for the sale
or disposition by Company of all or substantially all of Company's assets. For
purposes of this Section, the term "Continuing Director" shall mean (1) any
member of the Board, while such person is a member of the Board, who was a
member of the Board prior to the date of this Agreement, or (2) any person who
subsequently becomes a member of the Board, while such person is a member of the
Board (excluding an Acquiring Person or a representative of any Acquiring
Person), if such person's nomination for election or election to the Board is
recommended or approved by a majority of the Continuing Directors.

     (f)  Executive's Right to Terminate Upon Change of CEO. In the event that
          -------------------------------------------------
at any time during the Employment Term, the Company's chief executive officer is
not Alan Cohen, Chih-Ming Chen or Elliot Hahn and Executive does not have Good
Reason to terminate his employment pursuant to Section 6(b) hereof, Executive
shall nevertheless have the right, in the exercise of his sole discretion and
upon the provision of written notice to Company within eighteen (18) months
after the date a new chief executive officer is elected, to terminate his
employment hereunder as of the date specified in such written notice. In such
event, the parties shall discuss and agree upon the severance compensation
payable to Executive, with Executive being entitled, at a minimum, to the amount
set forth in Section 7(y) below with respect to options in existence prior to
the change of CEO.

                                       6
<PAGE>

     7.   Severance Compensation. In the event Executive's employment hereunder
is terminated by the Company pursuant to Section 6(b) hereof, or by Executive
pursuant to Section 6(c) or 6(e) hereof, the Company shall (w) pay Executive a
lump sum payment (the "Severance Payment") of three (3.0) times the highest
annual salary and annual bonus amounts Executive received during the preceding
three years (less applicable income taxes), within thirty (30) days of such
written notice, (x) continue to pay and provide Executive with one year of
health and dental insurance coverage (as reflected in Section 4(B)(2) above) for
a period of at least 12 months, (y) vest in full any installments of shares
under stock option agreements, stock, stock appreciation rights and all other
awards granted to executive between Company and Executive which, but for this
agreement, would not yet be exercisable or vested on such date, and allow
Executive to exercise said benefit, in full, for the entire remaining period
specified in such agreements (but in no event for a period less than 3 months
following such termination), and (z) pay an additional amount representing a
gross-up of any federal and state and local income tax liability arising from
any amounts payable pursuant to this Agreement which are considered to be a
"parachute payment" under Internal Revenue Code ss.280G and the regulations
promulgated thereunder.

     8.   Confidential Information. Executive recognizes and acknowledges that
the list of Company's customers, as it may exist from time to time, its
financial data, and its future plans and its trade secrets are valuable, special
and unique assets of the Company. At no time will Executive disclose any such
list or information, or any part thereof to any person, firm, corporation,
association or other entity for any unauthorized reason or purpose whatsoever.
In the event of a breach or threatened breach by Executive of the provisions of
this Paragraph, Company shall notify Executive, in writing, of the nature of his
breach of the provisions hereof, and if such breach is repeated and continuing,
shall be entitled to an injunction restraining Executive from disclosing, in
whole or in part, such list or information, or from rendering any services to
any person, firm, corporation, association or other entity to whom such list or
information, in whole or in part, has been disclosed or is threatened to be
disclosed. Nothing herein shall be construed as prohibiting Company from
pursuing any other remedies available to it for such breach or threatened
breach, including recovery of damages from Executive.

     9.   No Duty to Mitigate; Set-off. The Company agrees that if the
Executive's employment is terminated during the term of this Agreement, the
Executive shall not be required

                                       7
<PAGE>

to seek other employment or to attempt in any way to reduce any amounts payable
to the Executive by the Company pursuant to this Agreement. Further, the amount
of the Severance Compensation provided for in this Agreement shall not be
reduced by any compensation earned by the Executive or benefit provided to the
Executive as the result of employment by another employer or otherwise. Except
as otherwise provided herein, the Company's obligations to make the payments
provided for in this Agreement and otherwise to perform its obligations
hereunder shall not be affected by any circumstances, including without
limitation, any set-off, counterclaim, recoupment, defense or other right which
the Company may have against the Executive. The Executive shall retain any and
all rights under all pension plans, welfare plans, equity plans and other plans,
including other severance plans, under which the Executive would otherwise be
entitled to benefits.

     10.  Notices. All notices required to be given under this Agreement shall
be in writing, sent certified mail, return receipt requested, postage prepaid,
to the following addresses or to such other addresses as either may designate in
writing to the other party:

          (A)  If to Company, then:

          4955 Orange Drive
          Davie, Florida 33314
          Att: Chief Executive Officer
               with a copy to:

          4955 Orange Drive
          Davie, Florida 33314
          Att: Chief Legal Officer

          (B)  If to Executive, then:

          21205 Yacht Club Drive, Apt. 1506
          Aventura, Florida 33180

     11.  Arbitration. Any disputes arising out of or in connection with this
Agreement or any of its provisions, including but not limited to the alleged
breach of the provisions of this Agreement, shall be submitted to and determined
by arbitration conducted in accordance with the Rules of the American
Arbitration Association. The award rendered by the Arbitrator may be entered as
a judgment (with full binding, force and effect) in any court having
jurisdiction thereof. This Agreement shall constitute a written agreement to
submit any such dispute or controversy to arbitration within the meaning of the
Florida Arbitration Code and shall confer

                                       8
<PAGE>

jurisdiction on the Courts of the State of Florida to enforce such agreement to
arbitrate and to enter judgment on an award in accordance with said Florida
Arbitration Code.

     12.  Attorneys' Fees. The successful party to any arbitration or litigation
between or among any of the parties to this Agreement shall be entitled to
recovery a reasonable attorney's fees, arbitration fees and court costs. The
court or arbitrator may apportion fees or award fees based upon success in
various claims or parts of any arbitration or litigation.

     13.  Governing Law. This Agreement shall be governed by and construed in
accordance with the internal laws of the State of Florida. Any arbitration,
lawsuits or other proceedings related to this Agreement or the transactions
herein described shall be commenced and held in Dade or Broward County, Florida.

     14.  Waiver. The waiver by either party hereto of any breach of any
provision of this Agreement shall not operate or be construed as a waiver of any
subsequent breach by either party hereto.

     15.  Entire Understanding. This Agreement contains the entire understanding
of the parties relating to the employment of Executive by Company. It may not be
changed orally but only by an agreement in writing signed by the party or
parties against whom enforcement of any waiver, change, modification, extension
or discharge is sought.

     16.  Binding Effect. This Agreement shall be binding upon and inure to the
benefit of Company, its successors and assigns and Executive and his heirs and
legal representatives.

     17.  Assignment. Executive acknowledges that the services to be rendered by
him are unique and personal. Accordingly, Executive may not assign any of his
rights (except as specifically permitted herein) or delegate any of his duties
or obligations under this Agreement, except with the written permission of
Company.

     IN WITNESS WHEREOF, the parties hereto have hereunto set their hands and
seals the date and year first above written.

Attest:                                 ANDRX CORPORATION

_____________________________           By: /s/ Elliot F. Hahn
                                           ---------------------------

In the presence of:

/s/ Allison Lichter                     /s/ Scott Lodin
-----------------------------           ------------------------------
                                        Scott Lodin

                                       9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}]]